A systematic review of 74 studies found that the antimicrobial peptide LL-37 correlates with periodontal disease severity, suggesting it could serve as a clinical biomarker for gum disease.
74 clinical studies reviewedLL-37 consistently correlated with periodontal disease severity across multiple clinical studies, making it the strongest biomarker candidate
What the researchers found
From 1,267 initially identified publications, 74 clinical studies met inclusion criteria. Cathelicidin (LL-37), alpha-defensins, and beta-defensins 1-3 were the most studied antimicrobial peptides in periodontal contexts. LL-37 showed significant correlations with clinical periodontal indices (probing depth, clinical attachment loss) and bacteriological indices. Results for human beta-defensins (hBDs) were inconsistent across studies due to heterogeneous methodologies, diagnostic criteria, and assay techniques. LL-37 and alpha-defensins were identified as the most promising candidates for periodontal biomarkers.
Why it matters
Periodontal disease affects nearly half of adults and is linked to heart disease, diabetes, and other systemic conditions. Currently, diagnosis relies on physical measurements that detect disease after it has already progressed. If antimicrobial peptides like LL-37 can serve as early biomarkers in saliva or gum fluid, they could enable earlier detection and intervention through simple, non-invasive tests.
How the study worked
Systematic review searching MEDLINE-PubMed and EMBASE databases, identifying 1,267 publications. Inclusion was limited to clinical studies measuring antimicrobial peptide expression or production in human adult oral fluids (gingival crevicular fluid or saliva) or oral tissues. Seventy-four studies met the final inclusion criteria.
What this study cannot tell us
Significant heterogeneity across the 74 included studies in terms of periodontal disease definitions, assay methods, sample types, and patient populations. This prevented meta-analysis for most peptides. The inconsistent beta-defensin results highlight the need for standardized methods. Most studies were cross-sectional, limiting causal conclusions about whether peptide changes cause or result from disease.
How to read the evidence
This is a systematic review of 74 clinical studies, representing a thorough synthesis of available evidence. However, the inability to perform meta-analysis due to study heterogeneity and the inconsistent defensin results limit the overall strength of conclusions.
When this study was published
Published in 2019, this review synthesizes research accumulated over the prior decade on antimicrobial peptides in periodontal disease. The field has continued to advance with standardized assay development.
The bigger picture
The oral cavity is a rich source of antimicrobial peptides that form the first line of immune defense. Understanding how these peptides change with disease could transform periodontal diagnostics from invasive probing to simple saliva tests. This also connects to broader research on how oral health peptides relate to systemic inflammatory conditions.
Questions still open
- Could a saliva-based LL-37 test be developed for clinical screening of periodontal disease?
- Do antimicrobial peptide levels predict disease progression or treatment response in periodontal patients?
- Could therapeutic administration of LL-37 or defensins help treat or prevent periodontal disease?
Common questions
What are antimicrobial peptides and why are they in your mouth?
Could testing saliva replace dental probing for gum disease diagnosis?
Read the original research
Cationic antimicrobial peptides and periodontal physiopathology: A systematic review.
Journal of periodontal research, 54(6), 589-600
Citation
Jourdain, Marie-Laure; Velard, Frédéric; Pierrard, Loïc; Sergheraert, Johan; Gangloff, Sophie C; Braux, Julien. (2019). Cationic antimicrobial peptides and periodontal physiopathology: A systematic review.. Journal of periodontal research, 54(6), 589-600. https://doi.org/10.1111/jre.12676